Applied Therapeutics Inc
$ 0.11
-1.30%
26 Dec - close price
- Market Cap 16,435,800 USD
- Current Price $ 0.11
- High / Low $ 0.11 / 0.11
- Stock P/E N/A
- Book Value N/A
- EPS -0.10
- Next Earning Report 2026-03-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.88 %
- ROE -6.80 %
- 52 Week High 1.50
- 52 Week Low 0.10
About
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in New York, specializing in the development of innovative therapies to address critical unmet medical needs in cardiovascular diseases, galactosemia, and complications associated with diabetes. With a robust pipeline of novel compounds, the company is committed to cutting-edge research aimed at delivering patient-centric solutions. As it advances its drug candidates through clinical trials, Applied Therapeutics is positioned to play a transformative role in improving treatment outcomes within its focused therapeutic areas.
Analyst Target Price
$0.25
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-13 | 2025-08-13 | 2025-05-07 | 2024-12-31 | 2024-11-07 | 2024-08-07 | 2024-05-09 | 2024-03-06 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-03-23 |
| Reported EPS | -0.13 | -0.15 | 0.3281 | 0.33 | -0.48 | 0.02 | -0.67 | -0.34 | -0.47 | -0.37 | -0.18 | -0.16 |
| Estimated EPS | -0.14 | -0.17 | -0.185 | -0.1667 | -0.16 | -0.16 | -0.16 | -0.23 | -0.26 | -0.26 | -0.31 | -0.46 |
| Surprise | 0.01 | 0.02 | 0.5131 | 0.4967 | -0.32 | 0.18 | -0.51 | -0.11 | -0.21 | -0.11 | 0.13 | 0.3 |
| Surprise Percentage | 7.1429% | 11.7647% | 277.3514% | 297.9604% | -200% | 112.5% | -318.75% | -47.8261% | -80.7692% | -42.3077% | 41.9355% | 65.2174% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-13 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.1416 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: APLT
2025-12-19 09:00:00
Wolf Popper LLP announced a proposed class action settlement regarding purchasers of Applied Therapeutics, Inc. common stock between January 3, 2024, and December 2, 2024. The settlement, which totals $15,000,000 in cash and warrants, will be reviewed by the United States District Court Southern District of New York on March 19, 2026. Class members must submit a Proof of Claim by April 8, 2026, to participate.
2025-12-18 14:09:28
Faruqi & Faruqi, LLP is investigating potential claims against Applied Therapeutics, Inc. (NASDAQ: APLT) following alleged federal securities law violations. The firm encourages investors who purchased APLT securities between January 3, 2024, and December 2, 2024, and suffered losses, to come forward before the February 18, 2025 lead plaintiff deadline. The investigation stems from the FDA issuing a Complete Response Letter for govorestat and a subsequent Warning Letter, leading to significant stock price drops for Applied Therapeutics.
2025-12-16 16:09:35
Applied Therapeutics (APLT) recently formed a hammer chart pattern, indicating potential support and a trend reversal after a 46.8% loss in the past week. This technical signal, combined with an upward trend in earnings estimate revisions and a Zacks Rank #2 (Buy), suggests that the stock may be nearing a bottom and poised for a turnaround. Investors are encouraged to consider these factors as APLT's prospects appear to be improving.
2025-12-14 15:09:47
Applied Therapeutics (NASDAQ: APLT) has agreed to be acquired by Cycle Group Holdings Limited through a tender offer. Shareholders will receive $0.088 in cash per share plus one non-tradeable contingent value right (CVR), which could pay up to an additional $0.40 per share based on specific milestones for the AT-007 (govorestat) program and cash levels. The acquisition includes an $8.5 million unsecured loan from Cycle Group Holdings to Applied Therapeutics for working capital, bearing 24% annual interest.
2025-12-13 03:08:59
A class action securities lawsuit has been filed against Applied Therapeutics, Inc. (NASDAQ: APLT) for alleged securities fraud between January 3, 2024, and December 2, 2024. The lawsuit stems from a Complete Response Letter received by the company for its drug candidate govorestat, and a subsequent FDA "warning letter" regarding clinical trial deficiencies, leading to a significant drop in stock price. Investors who suffered losses during this period are encouraged to contact Levi & Korsinsky, LLP for potential recovery.
2025-12-12 14:09:37
Applied Therapeutics (APLT) has agreed to be acquired by Cycle Group Holdings Limited for an upfront cash payment of $0.088 per share and a contingent value right (CVR) tied to future FDA approvals and sales milestones. This deal has led to significant stock volatility, with analysts dissecting the uncertain value of the CVR against the backdrop of APLT's previous liquidity concerns and "going concern" warnings. The transaction, expected to close in Q1 2026, aims to leverage Cycle's resources to advance APLT's key asset, govorestat, though the CVR's non-transferable nature and long milestone windows introduce considerable investor uncertainty.
